Sydney Lupkin Sydney Lupkin is the pharmaceuticals correspondent for NPR.
Stories By

Sydney Lupkin

Sydney Lupkin

Pharmaceuticals Correspondent

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.

Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.

[+] read more[-] less

Story Archive

Acting FDA Commissioner Janet Woodcock said the agency would likely hold advisory panel meetings to consider changes in COVID-19 vaccines made in response to coronavirus variants. Scott Hensley/NPR hide caption

toggle caption
Scott Hensley/NPR

FDA Aims To Be 'Nimble' On COVID-19 Vaccine Changes For Variants

  • Download
  • <iframe src="https://www.npr.org/player/embed/966510470/966678340" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

With Coronavirus Variants On The Rise, Vaccine Companies And FDA Pivot

  • Download
  • <iframe src="https://www.npr.org/player/embed/966498583/966500994" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A worker carries boxes containing the Pfizer-BioNTech COVID-19 vaccine that were being prepared for shipment from a Pfizer facility in Portage, Mich., in December. Morry Gash/Pool/Getty Images hide caption

toggle caption
Morry Gash/Pool/Getty Images

Moderna Increases COVID-19 Vaccine Shipments While Pfizer Lags Behind

  • Download
  • <iframe src="https://www.npr.org/player/embed/962954518/962968015" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

How COVID-19 Vaccine Production Affects Vaccination Drives

  • Download
  • <iframe src="https://www.npr.org/player/embed/962946553/962946865" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A COVID-19 vaccine hub taking appointments only stands in Brooklyn as New York City begins to run low on doses Friday. Spencer Platt/Getty Images hide caption

toggle caption
Spencer Platt/Getty Images

Moderna And Pfizer Need To Nearly Double COVID-19 Vaccine Deliveries To Meet Goals

  • Download
  • <iframe src="https://www.npr.org/player/embed/959732433/959732667" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

The Nation's Coronavirus Vaccine Rollout Plan Faces Another Obstacle

  • Download
  • <iframe src="https://www.npr.org/player/embed/959552710/959557832" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Federal Deal To Increase Vaccine Production Could Give Some Employees Early Access

  • Download
  • <iframe src="https://www.npr.org/player/embed/957779150/957779151" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

People line up on Thursday for the first day of Clark County's pilot COVID-19 vaccination program at Cashman Center in Las Vegas. Ethan Miller/Getty Images hide caption

toggle caption
Ethan Miller/Getty Images

COVID-19 Supply Deal Lets Vaccine Maker Earmark Doses For Employees And Their Families

  • Download
  • <iframe src="https://www.npr.org/player/embed/957297895/957813232" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

U.S. Government To Buy Additional 100 Million Doses Of Pfizer COVID-19 Vaccine

  • Download
  • <iframe src="https://www.npr.org/player/embed/949751699/949751700" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Pfizer, BioNTech Reach Deal To Supply U.S. With More Vaccine Doses

  • Download
  • <iframe src="https://www.npr.org/player/embed/949542443/949547855" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A worker passes through the security gate at the Moderna campus in Norwood, Mass., one of the sites where the biotechnology company is manufacturing its COVID-19 vaccine. Joseph Prezioso/AFP via Getty Images hide caption

toggle caption
Joseph Prezioso/AFP via Getty Images

How Will Moderna Meet The Demand For Its COVID-19 Vaccine?

  • Download
  • <iframe src="https://www.npr.org/player/embed/947628608/947693915" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

If Pfizer Vaccine Is FDA Approved, What's Trump Administration's Plan For Buying It?

  • Download
  • <iframe src="https://www.npr.org/player/embed/945136585/945136586" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A vial of the COVID-19 vaccine developed by Pfizer and BioNTech that was used at the Royal Victoria Hospital in Belfast, U.K., on Tuesday. Liam McBurney/Bloomberg via Getty Images hide caption

toggle caption
Liam McBurney/Bloomberg via Getty Images

Novavax released its federal contract to develop and supply a COVID-19 vaccine. The agreement reveals terms that weren't previously known. Bloomberg via Getty Images hide caption

toggle caption
Bloomberg via Getty Images